Mar 08, 2022
Sana Biotechnology to Present Preclinical Data on its Engineered Hypoimmune Allogeneic CAR T Cells at the 2022 American Association for Cancer Research Annual Meeting
Jan 11, 2022
Sana Biotechnology Obtains Exclusive License from National Institutes of Health for CD22 CAR Construct
Jan 10, 2022
Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics Announce Non-Exclusive License Agreement for Clinically Validated BCMA CAR Construct
Jan 04, 2022
Sana Biotechnology to Present at the 40th Annual J.P. Morgan Healthcare Conference
Displaying 11 - 14 of 14